Morgan Stanley Maintains BioNTech(BNTX.US) With Hold Rating, Maintains Target Price $101

Morgan Stanley analyst Terence Flynn maintains $BioNTech(BNTX.US)$ with a hold rating, and maintains the target price at $101.According to TipRanks data, the analyst has a success rate of 65.1% and a

Futu NewsJul 1 21:31 · Ratings

Morgan Stanley Sticks to Its Hold Rating for BioNTech SE (BNTX)

TipRanksJul 1 20:35

Andreas & Thomas Struengmann Award Honors HAYA Therapeutics Co-founders as Inaugural Winners

BusinesswireJul 1 13:00

European Equities Traded in the US as American Depositary Receipts Nudge Higher in Friday Trading

MT NewswiresJun 28 23:06

Pfizer (PFE), BioNTech's Updated COVID-19 Jab Gets CHMP Nod

Yahoo FinanceJun 28 23:02

One graphic to understand | the June bull and bear stocklist of U.S. stocks is released! Optional consumer and technology sectors are performing strongly, Arm rose more than 38%, and Adobe rose nearly 23%.

The three major US stock indexes rose collectively this month, putting a perfect end to the first half of the year. Large-cap tech stocks continued their rally, driving the Nasdaq up by 6.71% this month, the best performer. The S&P 500 rose 3.89% this month and the Dow Jones rose 1.23%.

Futu NewsJun 28 19:50